Literature DB >> 10792093

Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate.

T Krupski1, G R Petroni, H F Frierson, J U Theodorescu.   

Abstract

OBJECTIVES: Angiogenesis has been shown to be related to p53 and retinoblastoma gene function as well as to neuroendocrine differentiation (as measured by chromogranin A staining) in prostate tumors. Studies have indicated that immunohistochemical assessment of p53, retinoblastoma, and chromogranin A in prostate cancers treated by radical prostatectomy can be useful in predicting disease-specific survival, whereas the degree of microvessel density (MVD), a measure of angiogenesis, correlates with disease recurrence. The ability of MVD, however, to predict disease-specific survival either alone or in conjunction with other prognostic factors has not yet been evaluated. The purpose of our study was to determine the relative importance of p53, retinoblastoma, and chromogranin A as well as MVD in the prediction of disease-specific survival following radical prostatectomy in conjunction with classical pathologic assessment.
METHODS: From 1970 to 1984, radical prostatectomy was performed on 75 patients with clinical Stage A2 to B2 adenocarcinoma of the prostate. No neoadjuvant or adjuvant treatments were given, and patients were followed until death. Prostatectomy specimens were examined to evaluate conventional pathologic parameters. In addition, the tissue was immunohistochemically stained for p53, retinoblastoma, chromogranin A, and endothelial cells. A previously described computerized imaging system analyzed the microvessels and computed both "optimized" and "area-weighted" MVD scores. Proportional hazard models were used to investigate the simultaneous association of these variables with disease-specific survival.
RESULTS: Of the 75 patients, 4 had follow-up of less than 3 months, and 29 patients had inadequate tissue for analysis of all immunohistochemical markers. The analyzed subset of 42 patients was found to be representative of the cohort of 71 patients. Multivariate analysis revealed that p53 and retinoblastoma have the greatest prognostic importance regarding disease-specific survival. Chromogranin A and optimized or area-weighted MVD scores were of no additional value when p53 and retinoblastoma were assessed.
CONCLUSIONS: Microvessel density, as a determinant of angiogenesis and chromogranin A, does not seem to add significantly to the prognostic disease-specific survival information provided by conventional pathology combined with p53 and retinoblastoma assessment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792093     DOI: 10.1016/s0090-4295(99)00598-1

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

Review 1.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

2.  p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer.

Authors:  Panagiotis J Vlachostergios; Foteini Karasavvidou; Anna Patrikidou; Ioannis A Voutsadakis; Grigorios Kakkas; George Moutzouris; Elias Zintzaras; Danai D Daliani; Michael D Melekos; Christos N Papandreou
Journal:  Pathol Oncol Res       Date:  2011-07-23       Impact factor: 3.201

3.  The prognostic value of p53 and DNA ploidy following radical prostatectomy.

Authors:  C Deliveliotis; A Skolarikos; A Karayannis; V Tzelepis; N Trakas; E Alargof; V Protogerou
Journal:  World J Urol       Date:  2003-07-03       Impact factor: 4.226

Review 4.  Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.

Authors:  William D Figg; Erwin A Kruger; Douglas K Price; Sonia Kim; William D Dahut
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

5.  Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study.

Authors:  Lorelei A Mucci; Anna Powolny; Edward Giovannucci; Zhiming Liao; Stacey A Kenfield; Rulong Shen; Meir J Stampfer; Steven K Clinton
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

6.  Prognostic factors in prostate cancer.

Authors:  A Buhmeida; S Pyrhönen; M Laato; Y Collan
Journal:  Diagn Pathol       Date:  2006-04-03       Impact factor: 2.644

Review 7.  The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.

Authors:  Naveen Kachroo; Vincent J Gnanapragasam
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-28       Impact factor: 4.553

8.  The prognostic significance of vasohibin-1 expression in patients with prostate cancer.

Authors:  T Kosaka; Y Miyazaki; A Miyajima; S Mikami; Y Hayashi; N Tanaka; H Nagata; E Kikuchi; K Nakagawa; Y Okada; Y Sato; M Oya
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.